Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Gains from Investment Securities: 2022-2025

Historic Gains from Investment Securities for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $699,000.

  • Taysha Gene Therapies' Gains from Investment Securities rose 185.24% to $699,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $391,000, marking a year-over-year decrease of 98.85%. This contributed to the annual value of $3.7 million for FY2024, which is 48.33% down from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Gains from Investment Securities is $699,000, which was up 621.64% from -$134,000 recorded in Q2 2025.
  • Taysha Gene Therapies' Gains from Investment Securities' 5-year high stood at $100.8 million during Q3 2023, with a 5-year trough of -$65.7 million in Q4 2023.
  • Its 3-year average for Gains from Investment Securities is $4.0 million, with a median of -$102,000 in 2025.
  • The largest annual percentage gain for Taysha Gene Therapies' Gains from Investment Securities in the last 5 years was 2,353.60% (2023), contrasted with its biggest fall of 16,658.69% (2023).
  • Taysha Gene Therapies' Gains from Investment Securities (Quarterly) stood at $397,000 in 2022, then tumbled by 16,658.69% to -$65.7 million in 2023, then spiked by 99.89% to -$72,000 in 2024, then skyrocketed by 185.24% to $699,000 in 2025.
  • Its Gains from Investment Securities stands at $699,000 for Q3 2025, versus -$134,000 for Q2 2025 and -$102,000 for Q1 2025.